A Houston company with a promising immuno-oncology is one step closer to delivering its cancer-fighting drug to patients who need it. Photo via Getty Images

A Houston immuno-oncology company has recently made major headway with the FDA, including both a fast track and an orphan drug designation. It will soon start a phase 2 trial of its promising cancer fighting innovation.

Diakonos Oncology was born in 2016, the brainchild of Baylor researchers already hard at work in the realm of dendritic cell vaccines. Drs. Will Decker, Matt Halpert, and Vanaja Konduri partnered with Dan Faust, a Houston businessman and pharmacist, to bring their treatment to the public, says COO Jay Hartenbach.

The name Diakonos means “deacon or servant in Greek,” he explains. “A lot of companies end up focusing on treating a specific disease or cancer and what you end up having is a significant amount of potential but with a lot of tradeoffs and downsides. And so our goal is we need to eliminate the cancer but we can't harm or dramatically malign the patient in doing so.”

How do they do that? Because the therapy catalyzes a natural immune response, it’s the patient’s own body that’s fighting the cancer. Hartenbach credits Decker with the idea of educating dendritic cells to attack cancer, in this case, glioblastoma multiforme (GBM), one of the most aggressive cancers with which doctors and patients are forced to tangle.

“Our bodies are already very good at responding very quickly and aggressively to what it perceives as virally infected cells. And so what Dr. Decker did was basically trick the immune system by infecting these dendritic cells with the cancer specific protein and mRNA,” details Hartenbach.

Jay Hartenbach is the COO of Diakonos Oncology. Photo courtesy of Diakonos Oncology

But GBM isn’t the only cancer on which Diakonos Oncology has its sights set. Other notably stubborn-to-treat cancers that they’re working on include pancreatic cancer and angiosarcoma. The scientists are focused on meeting unmet medical needs, but also realize that treating such cancers would allow for the fastest determination of whether or not the treatment was effective.

The fast track designation, originally received last fall, means that the drug approval time for DOC1021, Diakonos’ glioblastoma vaccine, will be only six months. But Hartenbach highlights an additional boon, the fact that the special designation also allows for more frequent communications with the FDA.

“That’s very helpful for us, right as we're contemplating how to design the upcoming trials. From a business standpoint, it also is incredibly helpful because it provides a third party validation of what we're doing and the results that we're seeing,” he says.

What they’re seeing includes the survival of 13 out of 16 patients from the initial October 2021 enrollment. The three patients who passed away received the lowest dose of DOC1021. Hartenbach says that the remaining patients are thriving, with no serious adverse effects. With a median survival rate of 15 to 21 months, it’s hard to understate the significance of these patients’ success.

Diakonos Oncology is headquartered in Houston, with a staff of 10 in Space City and an additional eight distributed employees. Hartenbach says that the company’s hometown has been instrumental in its success. He mentions that the robust innovation of the Texas Medical Center meant that as the company has grown, there has never been a motivation to leave Houston.

“You're having a lot of both investment and companies actually moving to Houston,” Hartenbach says. “So we’ve been fortunate to have started there. There are bigger traditional biotech hubs, San Diego, Boston, and San Francisco, but Houston really is now putting itself on the map and it's getting a lot of attention.”

One of the companies responsible for that improved reputation? Diakonos Oncology and its promising approach to aggressive cancers.

A Houston health care company received the green light from the FDA to advance a treatment that's targeting a deadly cancer. Photo via Getty Images

Houston immunotherapy company achieves FDA designation for cancer-fighting vaccine

got the green light

The FDA has granted a Houston-based company a Fast Track designation.

Diakonos Oncology Corp. is a clinical-stage immuno-oncology company that has developed a unique dendritic cell vaccine, DOC1021. The vaccine targets glioblastoma multiforme (GBM), the most common and most lethal malignant brain tumor in adults. The aggressive tumors come with a life expectancy of about 15 months following diagnosis. About 7 percent of those diagnosed survive five years, while the 10-year outlook only sees a one-percent survival rate.

“The FDA’s decision acknowledges the potential of this new treatment approach for a very challenging disease,” Diakonos CEO Mike Wicks says in a press release. “Our protocol represents a first for cancer immunotherapy and could be viable for many types of cancers beyond GBM.”

FDA Fast Track designations are intended to expedite the haste with which drugs with early clinical promise are reviewed, likely taking them to market faster.

DOC1021 uses the body’s natural anti-viral immune response to fight GBM. The vaccine mimics viral infection with the patient’s cancer markers. Essentially, DOC1021 uses the body’s own natural ability to detect and eliminate infected cells.

The technology uses dendritic cells, white blood cells that are able to perceive threats, to its advantage. The unique cancer markers are loaded both internally and externally into the immune cells, just as they would simultaneously occur in a viral infection. The individualized treatment is administered through three precise injections that target deep cervical lymph node chains. By dosing this way, the immune responses are directed straight to the central nervous system.

The results have spoken for themselves: All of the patients who have tried the treatment have exceeded survival expectations. And just as importantly, DOC1021 appears to be extremely safe. No serious adverse effects have been reported.

“Because Phase I clinical trials are generally not statistically powered to demonstrate efficacy, detection of a statistically significant efficacy signal is very promising,” says William Decker, associate professor of immunology at Baylor College of Medicine and inventor of the DOC1021 technology.

The Phase 1 open-label trial of DOC1021 (NCT04552886) is currently taking place at both the University of Texas Health Science Center in Houston and at the MD Anderson Cancer Center at Cooper University Health Care in Camden, NJ. The trial is expected to complete this year.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Announcing the winners of the 2026 Houston Innovation Awards

The winners are...

After weeks of anticipation, InnovationMap is proud to unveil the winners of the 2026 Houston Innovation Awards, our sixth-annual program honoring the best and brightest in the local innovation community.

This year, the Houston Innovation Awards recognized more than 40 finalists in 10 categories. They are shaping the future of Houston innovation across a variety of industries — from deep tech and energy to healthcare and education.

Finalists and winners were determined by our esteemed panel of judges, comprised of 2025 award winners, as well as InnovationMap editorial leadership. One winner was determined by the public via an online competition: Startup of the Year.

In the weeks leading up to this announcement, InnovationMap shined a spotlight on all of this year's outstanding finalists in our special editorial series. Learn more about all of them — and their outstanding achievements — here.

Without further ado, here are the 2026 Houston Innovation Awards winners:

Minority-founded Business: HexaSpec

Rice University spinout HEXASpec is working to improve the sustainability and thermal conductivity of semiconductor chips. The company has developed breakthrough inorganic fillers that allow graphic processing units (GPUs) to use less water and electricity and generate less heat. HEXASpec was founded in 2025 by CEO Tianshu Zhai, CTO Jing Zhang, and chief product officer Chen-Yang Lin. It has raised $800,000 in pre-seed funding and another $1.5 million in non-dilutive grants. The startup won the Liu Idea Lab for Innovation and Entrepreneurship's H. Albert Napier Rice Launch Challenge in 2024 and the 2025 Energy Venture Day and Pitch Competition during CERAWeek in the TEX-E student track in 2025. It was awarded a $500,000 National Science Foundation Partnership for Innovation grant last summer.

Female-founded Business: ARIX Technologies

Energytech startup ARIX Technologies has developed a semiautonomous VENUS crawler robot to detect corrosion under insulation before it becomes a failure. The robots climb insulated piping in refineries, chemical plants, and energy facilities to capture inspection data without removing insulation or building scaffolding. ARIX's inspection portal then turns information from the inspection into data a company can act on. ARIX was founded in 2017 by Dianna Liu, who serves as director, and Head of Product Petter Wehlin. Craig Malloy serves as CEO. The company has raised more than $22 million in seed funding and a Series A round.

Health Tech Business: Prana Surgical

Prana Surgical is developing a minimally invasive surgical platform for small, hard-to-reach lung nodules that may be cancerous. The company's Prana System cleared U.S. Food and Drug Administration (FDA) approval earlier this year. Prana Surgical was originally founded as Prana Thoracic in 2022. It has participated in numerous accelerators, including the Texas Medical Center Innovation Accelerator in 2023 and the IGNITE Health accelerator in 2022. It raised $6 million in Series A funding rounds in 2023 and 2024, with a Series B currently ongoing. The company is currently moving into the next stage of clinical validation and revenue generation in the U.S., in addition to preparing its manufacturing and commercial infrastructure for broader use.

Deep Tech Business: Venus Aerospace

Spacetech company Venus Aerospace is developing a high-thrust rotating detonation rocket engine (RDRE) that replaces the subsonic combustion used in conventional rocket engines. The RDRE is a compact, simpler engine that can deliver up to 15 percent greater efficiency for defense and space applications. It completed its first U.S. flight test of the engine last summer. Venus Aerospace was founded in 2020 by CEO Cassie Duggleby and CTO Andrew Duggleby. It raised a $20 million Series A in 2022 and $42 million Series A2 in 2025. It closed a $91 million Series B earlier this year and expanded its leadership team. The company is working toward longer-duration and higher-thrust testing and advancing its flight program.

Energy Transition Business: Hertha Metals

Hertha Metals produces lower-cost, lower-emission steel and high-purity iron. The company has developed a single-step process that uses natural gas as a direct reductant instead of metallurgical coal, which cuts production costs by more than 25 percent and emissions by up to 50 percent, according to the company. The same process produces high-purity iron needed for high-purity steels and rare earth magnets. The company says it aims to "re-industrialize America’s production of critical materials."

Scaleup of the Year: Hertha Metals

Founded by CEO Laureen Meroueh in 2022, Hertha Metals emerged from stealth in 2025 with more than $17 million in venture capital funding. The company closed a $133.65 million Series A in October and also broke ground on its $100M high-purity iron factory known as Chalyx in Conroe.

Incubator/Accelerator of the Year: Activate

Hard tech incubator Activate supports scientists in "the outset of their entrepreneurial journey." The Houston hub was introduced in 2024, and joins others in Boston, New York, and Berkley, California—where Activate is headquartered. It named its third Houston cohort this summer. The two-year program graduated its first class of Houston fellows in 2026 and saw its first alumni IPO from Houston-based Fervo Energy, which previously participated in a Berkley cohort. Nationally, it has supported 346 fellows and 276 companies since 2015. Those companies have raised more than $6 billion in follow-on funding, according to Activate. In Houston, it has supported local startups like Solidec, FlowCellutions and Orbital Arc. Activate Houston is led by managing director Jeremy Pitts, who co-founded Greentown Labs in Boston. It is based out of the Ion.

Startup of the Year (People's Choice): Progress Report

Progress Report is a K-12 learning-intelligence platform designed to go beyond identifying that a student is struggling. It traces performance to learning gaps and prerequisite skills, helping educators understand where a student is struggling and what may be causing it. Progress Report recently released a fully built production platform and launched pilots with 35 educators and 200 students across Texas and Arizona.

Mentor of the Year: Kyle Judah, Liu Idea Lab at Rice University

Kyle Judah is the executive director of Lilie, where he mentors pre-seed student startups. He also mentors through organizations like TEX-E, Greentown Labs and Activate. Some of the startups he's mentored include Helix Earth Technologies, Tierra Climate, Solidec, HexaSpec, SteerBio and many others.

"[Being a mentor] means helping to ensure that the most people possible have the best shot possible at making their company a successful reality," Judah says. "It means, at its root, opening the aperture for what is possible for people, by believing in them before anyone else even understands what their ambitions are. Because belief is the most infectious thing in the world. And before digging into the work in the trenches, most times founders need to kickstart their journey by having someone from the outside believe in them, when there's no real evidence to support that belief. So I guess, mentorship is a pure form of entrepreneurial faith."

2026 Trailblazer Legacy Award: Don Kendall Jr.

This year, the Trailblazer Legacy Award is given posthumously to Don Kendall Jr., who died in September while on a trip to the Republic of the Congo with the Jane Goodall Institute, one of the many organizations he was deeply involved with. Kendall served as general partner of New Climate Ventures, a Houston-based early-stage venture capital firm that invests in next-gen energy, materials and fuel technologies and startups. The firm's portfolio includes Houston-based clean energy companies like Solidec, Syzygy Plasmonics and Rheom Materials.

Outside of the clean energy space, Kendall also served on the boards of the Jane Goodall Institute, Earthwatch International and Ecological Defense Group. He also served as vice chair of Houston Zoo Inc. and chair of its Conservation Committee. "[Don] paired a keen eye for potential with the relentless drive to unlock it. For Mars Materials, his early backing carried us through a critical valley when we needed belief the most, and his presence as a personal mentor is profoundly missed," says Innovation Awards judge Aaron Fitzgerald.

NASA leader calls SpaceX Starship's return from orbit 'almost magic'

Space news

SpaceX’s Starship made a triumphant return to Earth on Saturday, November 14, caught in midair by giant mechanical arms where its journey began 22 hours earlier.

It was the grand finale that Elon Musk and his team hoped for — the first-ever capture of a Starship flying back from space. But with the first-stage booster exploding shortly after Friday’s liftoff from Texas, the company fell short of its desired double catch, still the goal for accelerating moon and Mars travel.

Wreckage remained in the Gulf of Mexico, cordoned off by buoys, as the stainless steel, bullet-shaped spacecraft lowered itself upright at the launch pad.

The dramatic, sci-fi-like capture helped blot out the booster’s messy miss. Cameras panned the spacecraft up and down as it hung high above the ground, supported by the arms of the launch tower.

“Can you believe it?” SpaceX commentator Dan Huot shouted, dragging out each word. “Look at her! Baby, she’s back!”

Calling it an “epic day,” Musk later ascended the launch tower to take up-close video with his phone. He even hugged the spacecraft. “Looks great,” he reported via X.

SpaceX officials said the catch demonstrates the full reusability of Starship, crucial for rapid and low-cost recycling. Although Friday’s booster recovery failed, the company had already made three previous booster catches, validating the technique.

NASA welcomed Saturday’s news. The space agency is paying billions of dollars for Starship to land Artemis astronauts on the moon later this decade and help build a permanent lunar base. Musk’s ambitions are even grander: He wants to launch a fleet of Starships to build a city on Mars.

“It was almost magic,” NASA Administrator Jared Isaacman said via X. “Making more believers by the day ... one step closer to (emojis of the moon and the U.S. flag)."

The world’s largest and most powerful rocket — a 407-foot (124-meter) behemoth — blasted off late Friday afternoon from SpaceX’s Starship base near the U.S.-Mexican border. Separating neatly from its booster before things went awry, the upper-stage spacecraft soared into orbit and released 26 advanced Starlink satellites.

Starship continued circling the world 165 miles (265 kilometers) up, with live views of itself and Earth streaming down via Starlink. The spacecraft completed 14 laps around Earth, outshining the previous mission’s one to two laps.

It was SpaceX’s 15th flight of a full-scale Starship since 2023 and its only second trip to orbit.

SpaceX reported that everything on the spacecraft, including its vital heat shield, appeared to work well.

As for the booster, SpaceX’s Kate Tice said its engines stopped firing too soon on the way back down. The booster’s guidance system sensed it wasn’t in the right position and automatically initiated the watery detour and self-destruction. Engineers are still investigating the cause.

SpaceX expects to begin launching Starships from Florida’s Kennedy Space Center within the next few months. That is the starting point for NASA’s next Artemis mission, which will skip the moon and remain in orbit around Earth for lunar lander practice.

Artemis III’s four astronauts will attempt to dock their capsule with not only Starship but Blue Origin’s Blue Moon. The two companies will take turns delivering crews to the lunar surface. NASA is targeting as soon as 2028 for Artemis IV, humanity’s first moon landing since the Apollo era more than half a century ago.

University of Houston med school secures full accreditation

med school milestone

The University of Houston’s Tilman J. Fertitta Family College of Medicine has officially earned full accreditation after launching six years ago.

The designation comes from the Liaison Committee on Medical Education, which granted UH the maximum five-year review period available to a new medical school. To achieve the status, the committee reviewed the Fertitta College of Medicine's facilities, faculty and student outcomes, and curriculum to ensure the college met the highest standards in medical education.

“Full accreditation is not the finish line — it’s the foundation for everything we hope to accomplish in the years ahead,” Dr. Jonathan McCullers, vice president for health affairs at UH and dean of the Fertitta College of Medicine, said in a news release. “It strengthens our ability to attract outstanding students and faculty, expand our partnerships and prepare the next generation of physicians.”

Fertitta College of Medicine has graduated three classes of physicians, and every graduate from its most recent class secured a residency position. Enrollment has expanded from 30 students in its inaugural class to 65 students in its current class.

According to UH, about 70 percent of graduates have chosen to remain in Texas for further training, which is key to addressing the estimated 10,000 doctors needed to meet growing needs.

Fertitta College of Medicine opened for its first students in 2020, and now joins 14 other Texas schools as a fully LCME-accredited medical school. It also joins UTHealth Houston's McGovern Medical School and Baylor College of Medicine as one of three Houston-based LCME-accredited campuses.

The news comes after UH launched its health enterprise initiative, UH Health, in July and broke ground on its $77.5 million Medical Research Building next to the Fertitta College of Medicine last month.

“Building a medical school from the ground up is an extraordinary undertaking, and this milestone reflects the dedication of everyone who helped make it happen,” Dr. Stephen Scott, vice dean for education at the Fertitta College of Medicine, added in the release. “From developing an innovative curriculum to establishing the systems and partnerships that support our students, this has been a true team effort.”